Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

IDMC recommends continuation of Cel-Sci's pivotal trial of Multikine

Nov. 7, 2013

ImmunoGen discontinues IMGN-901 study in small-cell lung cancer

Nov. 6, 2013

3pRNA RIG-I agonist displays activity against melanoma

Nov. 6, 2013

CureVac collaborates with the Cancer Research Institute and Ludwig Cancer Research

Nov. 6, 2013

arGEN-X and de Duve Institute/UCL sign collaboration to develop immunomodulation therapy for cancer

Nov. 5, 2013

Farletuzumab misses phase II endpoint for NSCLC

Nov. 5, 2013

SymBio and Eisai discontinue Japanese phase II trial of Treakisym

Nov. 4, 2013

OncoMed Pharmaceuticals begins phase Ib trial of vantictumab with paclitaxel

Oct. 30, 2013

Vaccine targeting IDO safe and well tolerated in first-in-human study

Oct. 29, 2013

Mologen files application in Belgium to conduct trial in small cell lung cancer

Oct. 29, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...